Similar Median OS Between Ripretinib versus Sunitinib in Patients with Advanced GIST While Safety More Favourable for Ripretinib By Ogkologos - June 2, 2025 758 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the final overall survival and updated safety analysis of the INTRIGUE study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR How a Simple Tool Is Saving Lives of Children with Cancer... February 15, 2024 Sing Anyway May 5, 2021 New study to detect oesophageal cancer earlier April 28, 2022 FDA Approves Encorafenib with Binimetinib for Metastatic Non-Small Cell Lung Cancer... October 16, 2023 Load more HOT NEWS FDA Approves Capivasertib with Fulvestrant for Breast Cancer Adding Pembrolizumab to Platinum-Based Chemotherapy Improves Survival in Patients with Previously... Our sun safety messaging tours the UK with the NIVEA Sun... Nanoparticle Trains Immune Cells to Attack Cancer
